Prelude Therapeutics Unveils Promising Cancer Treatment Data at ESMO
Company Announcements

Prelude Therapeutics Unveils Promising Cancer Treatment Data at ESMO

The latest update is out from Prelude Therapeutics ( (PRLD) ).

Prelude Therapeutics has announced its presentation of clinical data on PRT3789, a groundbreaking treatment for cancers with SMARCA4 mutations, at the ESMO Congress 2024. This novel SMARCA2 degrader has shown promise in Phase 1 trials, demonstrating safety and potential efficacy, with Phase 2 dose recommendations expected by year-end. Prelude is also hosting an investor webcast to discuss these advancements, indicating a significant step forward in precision oncology.

See more data about PRLD stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskPrelude Therapeutics Shows Strong Q3 2024 Financial Results
TheFlyPrelude Therapeutics reports Q3 EPS (43c), consensus (47c)
TheFlyPrelude Therapeutics price target lowered to $1 from $3 at Barclays
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App